ARQT ARCUTIS BIOTHERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ARCUTIS BIOTHERAPEUTICS INC reported revenue of $130M (up 59.3% from a year earlier), net income of $15.0M and diluted EPS of $0.11; over the last four quarters revenue was $464M and net income $28.5M; for the fiscal year ended December 2025 revenue was $376M, up 91.3% on the year before.

ARQT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $376M, gross profit n/a, operating income −$12.2M, net income −$16.1M (margin -4.3%), EPS −$0.13
• Fiscal year ended Dec 2024: revenue $197M, gross profit n/a, operating income −$128M, net income −$140M (margin -71.3%), EPS −$1.16
• Fiscal year ended Dec 2023: revenue $59.6M, gross profit n/a, operating income −$241M, net income −$262M (margin -439.8%), EPS −$3.78
• Fiscal year ended Dec 2022: revenue $3.69M, gross profit n/a, operating income −$302M, net income −$311M (margin -8449.8%), EPS −$5.66
• Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$207M, net income −$206M (margin n/a), EPS −$4.18

ARQT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $130M (up 59.3% year over year), net income $15.0M, EPS $0.11
• Quarter ended Mar 31, 2026: revenue $105M (up 60.1% year over year), net income −$11.3M, EPS −$0.09
• Quarter ended Dec 31, 2025 (from the annual report): revenue $130M (up 81.5% year over year), net income $17.4M, EPS $0.14
• Quarter ended Sep 30, 2025: revenue $99.2M (up 121.7% year over year), net income $7.41M, EPS $0.06
• Quarter ended Jun 30, 2025: revenue $81.5M (up 164.1% year over year), net income −$15.9M, EPS −$0.13
• Quarter ended Mar 31, 2025: revenue $65.8M (up 32.8% year over year), net income −$25.1M, EPS −$0.20
• Quarter ended Dec 31, 2024 (from the annual report): revenue $71.4M (up 427.6% year over year), net income −$10.8M, EPS −$0.09
• Quarter ended Sep 30, 2024: revenue $44.8M (up 17.4% year over year), net income −$41.5M, EPS −$0.33
• Quarter ended Jun 30, 2024: revenue $30.9M (up 494.6% year over year), net income −$52.3M, EPS −$0.42
• Quarter ended Mar 31, 2024: revenue $49.6M (up 1682.4% year over year), net income −$35.4M, EPS −$0.32
• Quarter ended Dec 31, 2023 (from the annual report): revenue $13.5M (up 356.8% year over year), net income −$66.3M, EPS −$0.58
• Quarter ended Sep 30, 2023: revenue $38.1M (up 5156.4% year over year), net income −$44.8M, EPS −$0.73
• Quarter ended Jun 30, 2023: revenue $5.19M, net income −$71.0M, EPS −$1.16
• Quarter ended Mar 31, 2023: revenue $2.78M, net income −$80.1M, EPS −$1.31
• Quarter ended Dec 31, 2022 (from the annual report): revenue $2.96M, net income −$72.0M, EPS −$1.19
• Quarter ended Sep 30, 2022: revenue $725K, net income −$108M, EPS −$1.89
• Quarter ended Jun 30, 2022: revenue $0, net income −$67.4M, EPS −$1.31
• Quarter ended Mar 31, 2022: revenue $0, net income −$64.3M, EPS −$1.27
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$71.3M, EPS −$1.44
• Quarter ended Sep 30, 2021: revenue $0, net income −$57.0M, EPS −$1.14

ARQT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$5.63M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$112M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$247M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$258M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$175M, share buybacks n/a

ARQT balance sheet

• Jun 30, 2026: cash $34.1M, total assets $489M, total liabilities $268M, shareholders' equity $221M, long-term debt $102M
• Mar 31, 2026: cash $34.8M, total assets $460M, total liabilities $270M, shareholders' equity $190M, long-term debt $101M
• Dec 31, 2025: cash $42.9M, total assets $433M, total liabilities $243M, shareholders' equity $189M, long-term debt $108M
• Sep 30, 2025: cash $47.1M, total assets $371M, total liabilities $213M, shareholders' equity $158M, long-term debt $107M
• Jun 30, 2025: cash $72.7M, total assets $352M, total liabilities $213M, shareholders' equity $139M, long-term debt $107M
• Mar 31, 2025: cash $53.1M, total assets $344M, total liabilities $201M, shareholders' equity $143M, long-term debt $108M
• Dec 31, 2024: cash $71.3M, total assets $349M, total liabilities $191M, shareholders' equity $158M, long-term debt $107M
• Sep 30, 2024: cash $135M, total assets $437M, total liabilities $281M, shareholders' equity $157M, long-term debt $105M

What is ARQT's revenue?

ARCUTIS BIOTHERAPEUTICS INC reported $464M of revenue over its last four quarters, through June 30, 2026.

Is ARQT profitable?

Yes. ARCUTIS BIOTHERAPEUTICS INC earned $28.5M over the last four quarters.

What is ARQT's EPS?

Diluted earnings per share over the last four quarters were $0.22; $0.11 in the latest quarter.

ARQT ownership and insider trades · All stocks